Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $198.85 ($1.0M) on 2026-04-01, disclosed to the SEC on 2026-04-02.
Scheduled sale ($1.0M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $198.85 | 460 | $91K | 9.1% |
| 2 | $199.72 | 1,302 | $260K | 25.8% |
| 3 | $200.94 | 1,238 | $249K | 24.7% |
| 4 | $201.90 | 700 | $141K | 14.0% |
| 5 | $203.22 | 963 | $196K | 19.4% |
| 6 | $204.50 | 337 |
| $69K |
| 6.8% |
| Total | $201.24 avg | 5,000 | $1.0M | 100% |
| Filing → |
| LGND | SELL | 2026-08-04 | $1.4M | — | Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |